Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 - Wikidata - awgldk - TriplyDB

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

http://www.wikidata.org/entity/Q36088950

about

Oncolytic viruses as therapeutic cancer vaccines Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma Pancreatic cancer from bench to bedside: molecular pathways and treatment options Viro-immune therapy: A new strategy for treatment of pancreatic cancer Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses Molecular imaging of oncolytic viral therapy Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates Crystal structure of poxvirus thymidylate kinase: An unexpected dimerization has implications for antiviral therapy A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses Synergistic interaction between oncolytic viruses augments tumor killing.Oncolytic viruses: From bench to bedside with a focus on safety.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.Gene therapy progress and prospects cancer: oncolytic viruses.Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment.A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines.The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Effective oncolytic vaccinia therapy for human sarcomas.Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy Features of the Antitumor Effect of Vaccinia Virus Lister Strain Regulating cytokine function enhances safety and activity of genetic cancer therapies Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1 Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination

P2860

Q21245758-1FDA4354-F66B-4A7D-8970-5B2B8B7D1BAC Q24607747-0E2BB839-07CC-4F6D-9D03-BF9FF0544A9D Q26747524-262A1FEF-67AE-44F3-B28A-BB96CAEDCFFD Q26774641-DEBE131A-6DA3-44EA-A8E5-BFDFF9A9A36D Q26801501-E2278839-2718-4611-A004-359E22C017FD Q26859879-90FD004D-A0AE-460A-8F1E-AC83F63CD683 Q26999406-5DF4B06F-1D9C-40A4-B741-C10FEA82F9C8 Q27007519-B3D44157-04E8-4AA8-8762-39D5402C3634 Q27652695-02334A3F-4F63-44A9-B17D-443827BAD3FA Q33554262-B088782B-D693-44CF-93F4-BEE8A1DFA958 Q33558337-155F0136-8D44-4BCF-8A70-F04360CB6236 Q33710420-202B252D-D925-4EB8-98E9-6CA656863C05 Q33713908-C97E392E-EA10-481A-8C05-645095A0EF1B Q33769835-905B68E8-1D4C-4FC9-B75B-CEF42B5A8ADB Q33808504-5D18E718-9A2E-4E89-8F07-4CB5F9BB7550 Q33906116-7B6BC373-C387-4C2B-9B73-0FA26286EDB1 Q33924550-7DE51A7C-3139-403B-8FEE-E490FE3C4686 Q33931616-40ECEA68-21C7-487B-9713-1AB25168BC59 Q34044071-AC69FD35-1AE6-42EF-B724-4752A44A2B2D Q34212910-D9DB6B04-35A7-40E1-9280-61E4D8ABBB7A Q34316241-63D7E6F3-3890-43BF-8609-0AA42CEDB85A Q34327051-3F0B60C8-B36A-4E81-8B50-636F63FE2C9F Q34343742-D51DDCB7-2C14-4303-9222-8F051ECBB840 Q34757261-CBF14E71-C5D7-4195-A36B-6EFE668E79E7 Q34770611-4ACC845E-E303-4F76-B618-1044D0D1EE02 Q34774805-D8A336E0-FD17-48EC-AB3C-E6FF2AC0D4FD Q35285695-96A1B228-B390-4727-9DE0-E13C4699045C Q35591435-93948889-876D-4C6F-B153-A6A5C8B8AF55 Q35623101-F4AC3824-9B4A-48DB-AC9D-DEC790C2977D Q35833186-F144DD36-EA6F-4A80-8E13-4E1488DE0A55 Q35876204-C9A6EA7C-DC0C-47C4-8DFF-DC5059A33500 Q35954052-9E037691-14E1-46F7-8169-BD152BF92591 Q36378248-42A0DF95-25D0-4098-8E5D-F01840E5F03B Q36507293-2DAFE738-E83F-402C-B7ED-3120DC7F237B Q36512561-302ED8FC-DFB8-443F-89C2-7A02B4628742 Q36520695-0F52FFD6-6F9A-4F05-B9D2-B97F03F30102 Q36582828-4E8C74C7-C9BC-410A-AC67-3710BE47DA97 Q36659289-DE7A82AD-3E4B-48F6-B704-00A853D26AF5 Q36664229-2F92994E-FF4E-485E-AD41-8609040A4EB2 Q36750814-94645B78-35FA-41E4-B684-CE45BD863EFD

P2860

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

http://www.wikidata.org/entity/Q36088950

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@ast

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@en

type

label

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@ast

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@en

prefLabel

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@ast

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@en

P1433

Q36088950-245FD340-5657-439B-BF19-AA5E52E14167

P1476

Q36088950-9C521742-375C-4CD6-92C5-2C07D87D95D3

P2093

Q36088950-150FEB4C-06AE-45A0-8CB3-0122141CC308

Q36088950-1F2FFEFB-DF80-446D-9058-494D7883209A

Q36088950-26C66C5E-2176-4279-8AC3-083417961044

Q36088950-48103B34-0C65-45E3-8659-3407B13A564E

Q36088950-5AC5D1EA-1289-44F6-9D38-27862B43E7BD

Q36088950-6A9963D2-5EA5-4ED9-88C6-00A436CF243A

Q36088950-6C3D53B5-6254-4FAB-B674-5D5423F37539

Q36088950-821DC427-DAE5-4C99-8327-440DBD81B2C9

Q36088950-9125DCB1-518F-4989-B133-F311FAD40B92

Q36088950-9254C1B5-8366-4993-B1EB-10E66E4CD8CB

P2860

Q36088950-036C5085-D192-4C95-B847-119935F1C1A1

Q36088950-044D09A8-1685-45FD-A662-43C6642BDCB9

Q36088950-4012F824-4BB7-4816-90C2-CEC2FB896620

Q36088950-47C8CB90-CA06-475C-8210-1731D07A625C

Q36088950-5B2C02C1-06AF-425D-87F3-1D4BFC9142CF

Q36088950-6A693C70-61D6-4B92-B5AF-7DE315520C3C

Q36088950-7577BE28-5885-4810-862A-9826CAFF0508

Q36088950-7AB09F55-6C28-40C7-8224-D1A656DF0865

Q36088950-7E752935-C73C-42A3-BD54-AA02F5030B13

Q36088950-7EE4462A-5051-466E-BED5-A681C2289D22

P304

Q36088950-B462D2CA-3D1C-4467-9FE4-B68F1AAD6D7B

P31

Q36088950-2E3D7AAA-0684-441F-A9F1-2AAB4C45AE69

P356

Q36088950-7591E4C5-44E3-4D59-A97D-6719F4C4B9F9

P407

Q36088950-AA61FECA-CDAF-4E39-B6C8-006D2F1A0D5C

P433

Q36088950-185EFC93-FB82-4ABE-9DB5-1572F9410FF1

P478

Q36088950-A68EE903-3C3F-4A44-BA7E-2055CFC03174

P50

Q36088950-23F048E8-DE53-4E15-B9EF-4E3581EBE881

Q36088950-26F3510B-56EB-4730-8DE7-55B2E214413F

P577

Q36088950-8693F87F-77F7-44EB-B960-D415137CCA51

P698

Q36088950-A1C8E3BA-05AD-47A4-9AF1-198F24C07878

P921

Q36088950-CC678929-AACA-4192-B783-BBF59A8F2715

P932

Q36088950-CD660584-1696-4086-BE6E-6437C262168F

P356

P1433

Journal of Clinical Investigation

P1476

Rational strain selection and ...... ive oncolytic poxvirus, JX-963

@en

P2093

David H Kirn

http://www.w3.org/2001/XMLSchema#string

David L Bartlett

http://www.w3.org/2001/XMLSchema#string

Dong-Ewon Lee

http://www.w3.org/2001/XMLSchema#string

Femina Kanji

http://www.w3.org/2001/XMLSchema#string

Jin-Han Cho

http://www.w3.org/2001/XMLSchema#string

Joel Werier

http://www.w3.org/2001/XMLSchema#string

Shizuko Sei

http://www.w3.org/2001/XMLSchema#string

Steve H Thorne

http://www.w3.org/2001/XMLSchema#string

Tae-Ho H Hwang

http://www.w3.org/2001/XMLSchema#string

William E O'Gorman

http://www.w3.org/2001/XMLSchema#string

P2860

Poxvirus pathogenesis

Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.

Recent progress in the battle between oncolytic viruses and tumours.

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

Deletion of the vaccinia virus growth factor gene reduces virus virulence

The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication.

Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

P304

3350-3358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI32727

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Christopher W Brown

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17965776

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2040321

http://www.w3.org/2001/XMLSchema#string